Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.51 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647993 | 0.80 | PIK3CD (0.48) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1647378 | 0.78 | GRIN2D (0.57) | LMNAMAPT | |
| SCHEMBL1647376 | 0.78 | GRIN2D (0.57) | LMNAMAPT | |
| SCHEMBL941899 | 0.77 | SLC6A2 (0.79) | SLC6A2SLC6A4BRCA1ATMTSHR | |
| SCHEMBL1647156 | 0.76 | DRD4 (0.50) | ALDH1A1MAPT | |
| SCHEMBL7241082 | 0.74 | SLC6A2 (0.71) | SLC6A2SLC6A4TSHRALDH1A1LMNA | |
| SCHEMBL15474985 | 0.74 | SLC6A2 (0.52) | SLC6A2SLC6A4BRCA1ATMTSHR | |
| SCHEMBL1646796 | 0.73 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL25134014 | 0.72 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPT | |
| SCHEMBL29927711 | 0.72 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | SLC6A2 2409/4885SLC6A4 2469/4885BRCA1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.